Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

Abstract:

:Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients with locally advanced or metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred in this setting. Several clinical trials have investigated the efficacy and toxicity-profile of second-line CT and indicated that selected patients may obtain significant benefit from it, also with regard to survival. However, definitive results from large randomized phase III studies are still lacking, and the evidence for clinical benefit of salvage CT is based on small phase II trials that evaluated different treatment schedules in heterogeneous populations. The main goal of this paper is reviewing this topic.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Custodio A,Puente J,Sastre J,Díaz-Rubio E

doi

10.1016/j.ctrv.2009.08.012

subject

Has Abstract

pub_date

2009-12-01 00:00:00

pages

676-84

issue

8

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(09)00126-1

journal_volume

35

pub_type

杂志文章,评审
  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?

    abstract::Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.03.125

    authors: Johannessen TC,Bjerkvig R,Tysnes BB

    更新日期:2008-10-01 00:00:00

  • Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

    abstract::Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers. Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients. Despite overexpress...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.001

    authors: Ocaña A,Amir E

    更新日期:2009-12-01 00:00:00

  • Neck lymph node metastases from unknown primary.

    abstract::Metastatic cervical carcinoma from unknown primary is a metastatic disease in the lymph nodes of the neck without any evidence of a primary tumour after appropriate investigation. The condition is rare and definite evidence is lacking for both diagnosis and treatment. In this review of the literature, we tried to draw...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.11.014

    authors: Arosio AD,Pignataro L,Gaini RM,Garavello W

    更新日期:2017-02-01 00:00:00

  • Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.

    abstract::Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.05.003

    authors: Liu S,Kurzrock R

    更新日期:2014-08-01 00:00:00

  • New approaches to the systemic treatment of melanoma.

    abstract::Metastatic melanoma is an incurable condition with a median survival of about 6 months. Chemotherapy can result in objective tumour responses but only in a minority of cases and remissions are short-lived, 3-6 months. DTJC is the most active single agent with response rates of 15-20% and although combination chemother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0138

    authors: Chowdhury S,Vaughan MM,Gore ME

    更新日期:1999-10-01 00:00:00

  • Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.

    abstract::Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers and remains a challenge in oncology. In 1997, gemcitabine became the standard of care in metastatic setting. In the last decades, despite a number of clinical trials assessing novel cytotoxic agents and cell signaling inhibitors, overall sur...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.10.002

    authors: El Maalouf G,Le Tourneau C,Batty GN,Faivre S,Raymond E

    更新日期:2009-04-01 00:00:00

  • Tolerability and safety of rituximab (MabThera).

    abstract::Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was est...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.05.007

    authors: Kimby E

    更新日期:2005-10-01 00:00:00

  • Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

    abstract::The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib have been incorporated into treatment paradigms for patients with advanced non-small cell lung cancer. These agents are particularly effective in a subset of patients whose tumors harbor activating epidermal growth...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.01.003

    authors: Giaccone G,Wang Y

    更新日期:2011-10-01 00:00:00

  • Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

    abstract:INTRODUCTION:Identification of membrane proteins expressed exclusively on tumor cells is a goal for cancer drug development. The receptor tyrosine kinase-like orphan receptor type 1 and 2 (ROR1/2), are type-I transmembrane proteins expressed in cancer but not in adult normal tissue. Here, we explore the prognostic role...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2019.05.006

    authors: Saleh RR,Antrás JF,Peinado P,Pérez-Segura P,Pandiella A,Amir E,Ocaña A

    更新日期:2019-07-01 00:00:00

  • Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.

    abstract::In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/s0305-7372(83)80013-9

    authors: Scheulen ME,Niederle N,Bremer K,Schütte J,Seeber S

    更新日期:1983-09-01 00:00:00

  • Progress in the surgical treatment of malignant liver tumors in children.

    abstract::During the last decade, important progress has been made in the surgical treatment of malignant liver tumors in children. For hepatoblastoma, there is a general consensus for combining surgical resection with neoadjuvant (and adjuvant) chemotherapy. Long-term disease-free survival of around 85-90% can be achieved for ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.013

    authors: Otte JB

    更新日期:2010-06-01 00:00:00

  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(93)90004-b

    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • Effects of hormonal treatment on lipids in patients with cancer.

    abstract::Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase high density lipoprotein cholesterol (HDL-C) concentration, but induce an elevation ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.09.007

    authors: Filippatos TD,Liberopoulos EN,Pavlidis N,Elisaf MS,Mikhailidis DP

    更新日期:2009-04-01 00:00:00

  • To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review.

    abstract:BACKGROUND:The association between alcohol intake and breast cancer recurrence or development of second primary breast cancer in the survivor population is unclear. The aim of this systematic review was to evaluate the existing evidence to assess the extent to which alcohol consumption is associated with breast cancer ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.010

    authors: Simapivapan P,Boltong A,Hodge A

    更新日期:2016-11-01 00:00:00

  • PARP inhibitors in ovarian cancer.

    abstract::Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways,...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.12.002

    authors: Franzese E,Centonze S,Diana A,Carlino F,Guerrera LP,Di Napoli M,De Vita F,Pignata S,Ciardiello F,Orditura M

    更新日期:2019-02-01 00:00:00

  • Unraveling galectin-1 as a novel therapeutic target for cancer.

    abstract::Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep proces...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.07.007

    authors: Astorgues-Xerri L,Riveiro ME,Tijeras-Raballand A,Serova M,Neuzillet C,Albert S,Raymond E,Faivre S

    更新日期:2014-03-01 00:00:00

  • Arsenical-based cancer drugs.

    abstract::Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As(III) and As(V). As(III), in particular, reacts with closely spaced protein thiols, forming stable cyclic dithioarsinite complexes in which both sulfur atoms are bound to arsenic. It is this reaction that is mostly responsible for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.05.001

    authors: Dilda PJ,Hogg PJ

    更新日期:2007-10-01 00:00:00

  • The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures.

    abstract::With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00038-5

    authors: Nuver J,Smit AJ,Postma A,Sleijfer DT,Gietema JA

    更新日期:2002-08-01 00:00:00

  • RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

    abstract::Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene express...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.08.004

    authors: Barata P,Sood AK,Hong DS

    更新日期:2016-11-01 00:00:00

  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.001

    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • Physical exercise interventions in haematological cancer patients, feasible to conduct but effectiveness to be established: a systematic literature review.

    abstract:PURPOSE:To summarize and define the methodological quality of primary research findings obtained in exercise interventions, aimed at improving physical function or psychological well-being in patients treated for haematological malignancies. METHODS:Relevant trials were identified through a computerized Mesh-search in...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.09.008

    authors: Liu RD,Chinapaw MJ,Huijgens PC,van Mechelen W

    更新日期:2009-04-01 00:00:00

  • The potential of melanoma antigen expression in cancer therapy.

    abstract::A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0126

    authors: Gillespie AM,Coleman RE

    更新日期:1999-08-01 00:00:00

  • Fertility preservation in cancer patients: the global framework.

    abstract::Cancer treatment is the most frequent cause of reduced fertility in cancer patients, with up to 80% of survivors affected. None of the established or experimental fertility preservation methods can assure parenthood, rather they may provide a future opportunity to overcome treatment induced sterility. Around 70-75% of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.001

    authors: Linkeviciute A,Boniolo G,Chiavari L,Peccatori FA

    更新日期:2014-09-01 00:00:00

  • Update on capecitabine alone and in combination regimens in colorectal cancer patients.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/S0305-7372(10)70020-7

    authors: Silvestris N,Maiello E,De Vita F,Cinieri S,Santini D,Russo A,Tommasi S,Azzariti A,Numico G,Pisconti S,Petriella D,Lorusso V,Millaku A,Colucci G

    更新日期:2010-11-01 00:00:00

  • A preclinical and clinical review of aflibercept for the management of cancer.

    abstract::Aflibercept, also known as vascular endothelial growth factor (VEGF)-Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only all forms of VEGF-A, but also VEGF-B and placental growth factor. It inhibits VEGF-induced angiogenesis in preclinical models. In t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.12.008

    authors: Gaya A,Tse V

    更新日期:2012-08-01 00:00:00

  • Cardiotoxicity associated with radiotherapy in breast cancer: A question-based review with current literatures.

    abstract::Radiotherapy is an indispensable unit of multidisciplinary treatment of breast cancer. Although the application of modern techniques has led to a significantly reduction in radiation-induced heart disease, it is still recognized as the leading causes of morbidity and mortality among breast cancer survivors. With the g...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.03.008

    authors: Zhu Q,Kirova YM,Cao L,Arsene-Henry A,Chen J

    更新日期:2018-07-01 00:00:00

  • Cardiovascular effects of breast cancer radiotherapy.

    abstract::Cardiac toxicity has been implicated as the primary reason for excess non-breast cancer mortality in early breast cancer radiotherapy studies. Refinements in radiotherapy techniques have allowed for a considerable reduction of this risk in the majority of breast cancer patients. Recent large population-based studies c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.07.011

    authors: Senkus-Konefka E,Jassem J

    更新日期:2007-10-01 00:00:00

  • Targeted therapies in advanced differentiated thyroid cancer.

    abstract::Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.002

    authors: Carneiro RM,Carneiro BA,Agulnik M,Kopp PA,Giles FJ

    更新日期:2015-09-01 00:00:00

  • A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer.

    abstract::Diffusion-weighted magnetic resonance imaging (DW-MRI) is used extensively to improve tumour detection and localization because it offers excellent soft tissue contrast between malignant and non-malignant tissues. It also provides a quantitative biomarker; the apparent diffusion coefficient (ADC) can be derived from D...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.03.010

    authors: Bollineni VR,Kramer G,Liu Y,Melidis C,deSouza NM

    更新日期:2015-06-01 00:00:00